Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Shares Outstanding (Diluted Average) (2016 - 2025)

IGC Pharma has reported Shares Outstanding (Diluted Average) over the past 11 years, most recently at $90.5 million for Q3 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 21.55% to $90.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $90.5 million through Sep 2025, up 21.55% year-over-year, with the annual reading at $76.5 million for FY2025, 30.04% up from the prior year.
  • Shares Outstanding (Diluted Average) was $90.5 million for Q3 2025 at IGC Pharma, up from $83.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $90.5 million in Q3 2025 and troughed at $53.7 million in Q3 2023.
  • The 3-year median for Shares Outstanding (Diluted Average) is $74.4 million (2024), against an average of $71.4 million.
  • Year-over-year, Shares Outstanding (Diluted Average) soared 38.59% in 2024 and then grew 14.03% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $57.0 million in 2023, then skyrocketed by 32.36% to $75.5 million in 2024, then grew by 19.82% to $90.5 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Shares Outstanding (Diluted Average) are $90.5 million (Q3 2025), $83.0 million (Q2 2025), and $76.5 million (Q1 2025).